An Evaluation of the Causes of Anemia in Patients With Heart Failure

Anemia in Chronic Heart Failure: Etiology, Comparisons With Renal Disease, and Relationships With Biomarkers and Left Ventricular Remodeling.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00834691

Acronym

ANCHOR

Enrollment

180

Registered

2009-02-03

Start date

2008-01-31

Completion date

Unknown

Last updated

2010-08-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anemia, Chronic Renal Failure, Heart Failure

Keywords

Inflammation, Oxidative stress, Estimated glomerular filtration rate

Brief summary

Anemia is frequent in patients with heart failure. Few studies have clearly addressed the causes of anemia in patients with HF. The purpose of this study is to evaluate differences in blood concentrations of various substances related to inflammation, oxidative stress, renal function and other processes between individuals with 1) heart failure and anemia, 2) heart failure without anemia and 3) patients with kidney disease without systolic heart failure. This study will help to better understand the reasons why some people with heart failure have anemia.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Groups 1 and 2 * Age \>18 years * Group 1: hemoglobin \< 120g/L in women and \< 130 g/L in men (in agreement with the WHO definition of anemia) * Group 2: hemoglobin \> or = 120g/L in women and \> or = 130 g/L in men * Patients with chronic HF referred to a specialized HF clinic, or with a diagnosis of HF at least 6 months prior to enrolment * NYHA functional class II-IV at the time of enrolment * Patients already on CHF medical therapy (ACEI or ARBs, beta-blockers if tolerated, with or without digoxin, and loop diuretics), at stable doses for \> or = 1 month * LVEF \< or = 40% within 6 months prior to patient enrolment, by echocardiography, radionuclide ventriculography or perfusion scan, or radiologic angiography Inclusion criteria - group 3 * Age \>18 years * At least moderate CRF (eGFR \< 60ml/min/1,73m2) * With or without anemia * LVEF \> or = 50% within 6 months prior to patient enrolment, by echocardiography, radionuclide ventriculography or perfusion scan, or radiologic angiography

Exclusion criteria

(all groups): * Recent acute renal failure episode (\< 1 month) * Red blood cells (or other blood component) transfusions or EPO therapy within 3 months prior to enrolment * Iron, B12 or folic acid supplements used to treat anemia (\< 3 months) * Evidence of active GI bleeding * Recent acute coronary syndrome or decompensated HF episode (\< 1 month) * Complex congenital heart disease * Known malignant hematologic or other active neoplasia * Immunosuppressive therapy, chemotherapy or radiotherapy within 3 months prior to enrolment * Recent acute decompensation of a chronic inflammatory disease (e.g. chronic inflammatory bowel disease, rheumatoid arthritis, collagen vascular disease) within 3 months prior to enrolment * Recent viral or bacterial syndrome (\< 2 weeks) * Active or recent viral hepatitis (\< 3 months) * Pregnant women * Potential for non compliance to tests involved in this protocol * Incapacity to provide informed consent

Design outcomes

Primary

Measure	Time frame
TNF alpha concentrations	Visit 2 (within 2 weeks of baseline visit)

Secondary

Measure	Time frame
Various echocardiographic measurements, markers of inflammation, oxydative stress, neurohormonal activity and myocardial extracellular matrix turnover will be measured	Visit 2 (within 2 weeks of baseline visit)

Countries

Canada

Outcome results